See the DrugPatentWatch profile for Comirnaty
When does the Comirnaty (Pfizer-BioNTech) patent expire—2041 or later?
Comirnaty’s intellectual-property timeline is not a single universal “expiry year” for the whole product. Different patents (covering the mRNA sequence, formulations, delivery methods, manufacturing processes, and specific claims in different countries) expire at different times, and the schedule can vary by jurisdiction. As a result, “2041” can appear online as an estimate or as the latest expiry date for one set of claims, but it is not guaranteed to be the final end of all relevant protection everywhere.
Which country’s 2041 date are people referring to?
Patent expiry depends on where the patents were filed and whether the patent term has been adjusted (for example, because of regulatory delays under local law). Without a specific jurisdiction and patent family number, it’s easy for multiple different “expiry dates” to get mixed together in summaries.
What types of patents could extend protection toward 2041?
If a “2041” date is cited for Comirnaty, it usually reflects one of these categories rather than a single basic patent:
- Formulation or dosing-related claims (for example, specific lipid nanoparticle or dosing regimens).
- Manufacturing and process claims (specific steps that make the product).
- Specific improvements or second-generation patents filed after the original breakthrough.
- Country-specific patent filings and claim scope within those filings.
What happens after patents expire—does that mean Comirnaty stops being protected?
Even after certain patents expire, other layers of protection can remain, such as:
- Regulatory exclusivity (distinct from patent rights) that can limit marketing of competitors even if patents are gone.
- Other patents that have not yet reached expiry, including process or improvement patents.
- Data protection and approvals-related exclusivities tied to how generics/biosimilars or follow-on products enter a market.
So a patent-expiry year does not automatically equal “no more protection” or “instant generic entry.”
Could generics or “follow-on” versions enter before 2041?
In many markets, competitors can enter without waiting for every patent in the portfolio to expire, depending on:
- Whether they design around active patents (avoid infringing claims).
- Whether they rely on later-expiring patents for specific process/formulation elements.
- Regulatory rules on how marketing authorization can be granted and what exclusivities still apply.
How to check the exact Comirnaty expiry date you care about (fastest way)
To verify whether “2041” is correct for your use case, you need:
- The country (e.g., US, EP/UK, Canada, etc.).
- The specific patent family or patent number being referenced.
- The claim type (composition, method of manufacture, dosing/formulation, etc.).
With those, you can map expiry and any term adjustments precisely.
If you tell me the country (and, if you have it, the patent number or a link where “2041” is mentioned), I can help interpret which patents are likely driving that date and what it means for market entry timelines.